IP Library Granted Patent US 8,084,040
Granted Patent B2
US 8,084,040 · App. 12/957,543 · Granted Dec 27, 2011

Use of bacterium for manufacture of a vaccine

Assignee: Intervet International B.V.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,084,040
App. No.
12/957,543
Granted
Dec 27, 2011
Kind
B2
Abstract

The present invention relates to the use of live attenuated bacteria for the manufacture of a vaccine for submucosal administration.

Claims (18)

1. A method for reducing the amount of adverse reactions in a mammal at an injection site of a live attenuated bacterial vaccine, wherein:

the method comprises administering submucosally the vaccine, whereby the amount of adverse reactions at the injection site is reduced,

the live bacterial vaccine comprises bacteria that cause abscess formation when administered intramuscularly, and

the reduction of the amount of adverse reactions is measured by the amount or size of abscesses at the mucosal injection site compared to an intramuscular injection site.

2. The method according to claim 1 , wherein the vaccine is administered into the submucosa of the labiae.

3. The method according to claim 1 , wherein the mammal is a horse.

4. The method according to claim 1 , wherein the mammal is a ruminant.

5. The method according to claim 1 , wherein the mammal is a pig.

6. The method according to claim 1 , wherein the mammal is a dog.

7. A method for systemic application of live attenuated bacteria to a mammal, wherein:

the method comprises administering the live attenuated bacteria submucosally to the mammal,

the live attenuated bacteria cause abscess and/or lesion formation in the mammal if the live attenuated bacteria are instead administered intramuscularly or intradermally to the mammal, and

any abscess and/or lesion formation at the site of the submucosal administration is less in total size than the abscess and/or lesion formation that would occur if the bacteria are instead administered intramuscularly or intradermally to the mammal.

8. A method according to claim 7 , wherein the live attenuated bacteria cause abscess and/or lesion formation in the mammal if the live attenuated bacteria are administered intramuscularly to the mammal.

9. The method according to claim 7 , wherein the mammal is a horse.

10. The method according to claim 7 , wherein the mammal is a ruminant.

11. The method according to claim 7 , wherein the mammal is a pig.

12. The method according to claim 7 , wherein the mammal is a dog.

Priority Claims (3)
EP 97202365 · Jul 29, 1997 · regional
EP 97202925 · Sep 24, 1997 · regional
EP 99200202 · Jan 26, 1999 · regional
Continuity (4)
Continuation 10731724 · Dec 8, 2003
Continuation 09492206 · Jan 27, 2000
Continuation In Part 09123735 · Jul 28, 1998
Related Publication 20110123571A1 · May 26, 2011